Carlo joins other leading authorities in drug discovery and development as part of the Biopharmaceuticals category in the Medicine Maker Power List. In his interview he reviews future trends in drug development and some of the defining moments of his…
IRBM and their collaborators’ at the universities of Strasbourg and Siena have recently published a paper in the ACS Medicinal Chemistry Letters which describes their approach to the identification of a 5-dihydroxypyrimidine-6-carboxamide substructure as a privileged scaffold of a new…
IRBM’s Chief Science Officer, Carlo Toniatti is once again featured in the Medicine Maker. This time he takes us on a journey from the clinic, to academia, to industry – where he spent over two decades developing anti-cancer drugs. Carlo…
A conversation with Matteo Liguori, Managing Director of IRBM
Fibro-adipogenic progenitors (FAPs) are known to cause muscle impairment in non-physiological settings, such as aging and myopathies, by promoting fibrosis and fat infiltration. IRBM and their collaborators at the University of Rome Tor Vergata, screened a library of 1,120 FDA/EMEA…
As the world is coming to terms with the terrific speed of the COVID19 pandemic and how it can dramatically change people, societies and even nations; our hearts go out to the many people who have been affected by this…
En este momento en el que el mundo se enfrenta a la tremendamente rápida difusión de la pandemia de Covid-19 y a los drasticos cambios en las personas, las sociedades e incluso las naciones, nuestros corazones están con la gran…
Le monde entier est confronté à la propagation très rapide du Covid 19 et personne ne sait comment le monde évoluera suite à cette crise. Toutes nos pensées vont vers ceux déjà atteints par ce virus sans précédent et nous…
Mentre il mondo si ritrova a fare i conti con la terribile diffusione della pandemia del Covid19 e come questa possa modificare drasticamente le abitudini delle persone, delle società e persino delle nazioni, il nostro pensiero è rivolto a tutti…